CN100566716C - 治疗高血脂症的组合物 - Google Patents
治疗高血脂症的组合物 Download PDFInfo
- Publication number
- CN100566716C CN100566716C CNB2008101104290A CN200810110429A CN100566716C CN 100566716 C CN100566716 C CN 100566716C CN B2008101104290 A CNB2008101104290 A CN B2008101104290A CN 200810110429 A CN200810110429 A CN 200810110429A CN 100566716 C CN100566716 C CN 100566716C
- Authority
- CN
- China
- Prior art keywords
- acipimox
- atorvastatin calcium
- group
- atorvastatin
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 血清总胆固醇(mmol/L) | 血清甘油三酯(mmol/L) | 低密度脂蛋白胆固醇(mmol/L) | 高密度脂蛋白胆固醇(mmol/L) |
正常对照组 | 1.74±0.19 | 0.71±0.17 | 0.25±0.14 | 0.95±0.19 |
模型对照组 | 13.73±2.80<sup>###</sup> | 2.23±0.54<sup>###</sup> | 9.26±1.21<sup>###</sup> | 3.87±0.86<sup>###</sup> |
阿昔莫司100mg/kg | 13.18±2.31 | 1.98±0.42 | 8.44±1.06 | 3.95±0.63 |
阿昔莫司200mg/kg | 10.82±3.05<sup>*</sup> | 1.78±0.55 | 8.23±0.40<sup>*</sup> | 4.35±0.55 |
阿昔莫司300mg/kg | 10.73±2.36<sup>*</sup> | 1.69±0.51<sup>*</sup> | 7.79±0.89<sup>**</sup> | 4.56±0.50 |
阿昔莫司400mg/kg | 11.18±2.47 | 1.72±0.54 | 7.65±0.40<sup>**</sup> | 4.70±0.58<sup>*</sup> |
阿托伐他汀钙2.5mg/kg | 13.64±1.82 | 2.22±0.56 | 8.87±0.74 | 4.16±0.91 |
阿托伐他汀钙5mg/kg | 12.45±2.67 | 1.93±0.52 | 8.17±0.80<sup>*</sup> | 4.21±0.59 |
阿托伐他汀钙10mg/kg | 11.23±2.12<sup>*</sup> | 1.80±0.28<sup>*</sup> | 8.07±0.55<sup>*</sup> | 4.48±0.41 |
阿托伐他汀钙20mg/kg | 10.27±2.67<sup>*</sup> | 1.72±0.47<sup>*</sup> | 7.78±0.26<sup>**</sup> | 4.52±0.32<sup>*</sup> |
阿托伐他汀钙30mg/kg | 9.91±2.65<sup>**</sup> | 1.78±0.55 | 7.98±0.60<sup>*</sup> | 4.59±0.27<sup>*</sup> |
阿昔200+阿托5mg/kg | 7.73±2.10<sup>***</sup> | 1.27±0.19<sup>**</sup> | 5.76±0.51<sup>***</sup> | 5.48±0.52<sup>***</sup> |
阿昔200+阿托10mg/kg | 7.02±1.62<sup>***</sup> | 1.19±0.15<sup>***</sup> | 5.37±0.41<sup>***</sup> | 5.97±0.30<sup>***</sup> |
阿昔200+阿托20mg/kg | 6.07±2.00<sup>***</sup> | 1.17±0.21<sup>***</sup> | 5.21±0.59<sup>***</sup> | 6.30±0.33<sup>***</sup> |
阿昔300+阿托5mg/kg | 8.01±2.06<sup>***</sup> | 1.23±0.23<sup>**</sup> | 5.15±0.70<sup>***</sup> | 5.75±0.58<sup>***</sup> |
阿昔300+阿托10mg/kg | 7.08±2.01<sup>***</sup> | 1.15±0.20<sup>***</sup> | 4.94±0.70<sup>***</sup> | 6.044.52<sup>***</sup> |
阿昔300+阿托20mg/kg | 6.93±2.59<sup>***</sup> | 1.14±0.26<sup>***</sup> | 4.80±0.48<sup>***</sup> | 6.16±0.5<sup>***</sup> |
阿昔400+阿托5mg/kg | 7.95±1.88<sup>***</sup> | 1.20±0.23<sup>***</sup> | 5.19±0.87<sup>***</sup> | 5.80±0.47<sup>***</sup> |
阿昔400+阿托10mg/kg | 7.27±2.55<sup>***</sup> | 1.15±0.31<sup>***</sup> | 5.17±0.76<sup>***</sup> | 5.95±0.45<sup>***</sup> |
组别 | 血清总胆固醇(mmol/L) | 血清甘油三酯(mmol/L) | 低密度脂蛋白胆固醇(mmol/L) | 高密度脂蛋白胆固醇(mmol/L) |
正常对照组 | 1.74±0.19 | 0.71±0.17 | 0.25±0.14 | 0.95±0.19 |
模型对照组 | 13.73±2.80<sup>###</sup> | 2.23±0.54<sup>###</sup> | 9.26±1.21<sup>###</sup> | 3.87±0.86<sup>###</sup> |
阿昔200+阿托5mg/kg | 7.73±2.10<sup>***★</sup> | 1.27±0.19<sup>**★</sup> | 5.76±0.51<sup>***★★</sup> | 5.48±0.52<sup>***</sup> |
阿昔200+阿托10mg/kg | 7.02±1.62<sup>***★</sup> | 1.19±0.15<sup>***★★</sup> | 5.37±0.41<sup>***★★</sup> | 5.97±0.30<sup>***★★</sup> |
阿昔200+阿托20mg/kg | 6.07±2.00<sup>***★★</sup> | 1.17±0.21<sup>***★★</sup> | 5.21±±0.59<sup>***★★</sup> | 6.30±0.33<sup>***★★</sup> |
阿昔300+阿托5mg/kg | 8.01±2.06<sup>***</sup> | 1.23±0.23<sup>**★</sup> | 5.15±0.70<sup>***★★</sup> | 5.75±0.58<sup>***★</sup> |
阿昔300+阿托10mg/kg | 7.08±2.01<sup>***★</sup> | 1.15±0.20<sup>***★★</sup> | 4.94±0.70<sup>***★★</sup> | 6.04±0.52<sup>***★★</sup> |
阿昔300+阿托20mg/kg | 6.93±2.59<sup>***★★</sup> | 1.14±0.26<sup>***★★</sup> | 4.80±0.48<sup>***★★</sup> | 6.16±0.51<sup>***★★</sup> |
阿昔400+阿托5mg/kg | 7.95±1.88<sup>***★</sup> | 1.20±0.23<sup>***★</sup> | 5.19±0.87<sup>***★★</sup> | 5.80±0.47<sup>***★★</sup> |
阿昔400+阿托10mg/kg | 7.27±2.55<sup>***★★</sup> | 1.15±0.31<sup>***★★</sup> | 5.17±0.76<sup>***★★</sup> | 5.95±0.45<sup>***★★</sup> |
阿昔300+普伐20mg/kg | 9.75±2.37<sup>**</sup> | 1.53±0.25<sup>**</sup> | 6.83±0.51<sup>***</sup> | 4.92±0.63<sup>*</sup> |
阿昔300+洛伐10mg/kg | 9.91±1.67<sup>**</sup> | 1.59±0.26<sup>**</sup> | 6.69±0.92<sup>***</sup> | 5.11±0.58<sup>**</sup> |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2008101104290A CN100566716C (zh) | 2005-04-29 | 2005-04-29 | 治疗高血脂症的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2008101104290A CN100566716C (zh) | 2005-04-29 | 2005-04-29 | 治疗高血脂症的组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800068997A Division CN1925857A (zh) | 2004-04-30 | 2005-04-29 | 治疗高血脂症的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101357131A CN101357131A (zh) | 2009-02-04 |
CN100566716C true CN100566716C (zh) | 2009-12-09 |
Family
ID=40329819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2008101104290A Expired - Fee Related CN100566716C (zh) | 2005-04-29 | 2005-04-29 | 治疗高血脂症的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100566716C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127115A (zh) * | 2011-11-30 | 2013-06-05 | 北京天衡药物研究院 | 一种治疗血脂异常的组合物 |
CN105232554A (zh) * | 2015-09-30 | 2016-01-13 | 青岛云天生物技术有限公司 | 一种治疗或预防肥胖型高血脂的药物组合物 |
-
2005
- 2005-04-29 CN CNB2008101104290A patent/CN100566716C/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
阿昔莫司和阿托伐他汀单独或合并应用治疗高脂血症的临床疗效和安全性比较. 胡大一等.中华心血管病杂志,第卷号:32卷第期号:增刊2期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN101357131A (zh) | 2009-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU732465B2 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
CA2897884A1 (en) | Solid solution compositions and use in chronic inflammation | |
CA3012675C (en) | A pharmaceutical composition for prevention of diet induced obesity | |
WO2009010810A2 (en) | Cardiovascular combinations comprising ace and hmg-co-a inhibitors | |
KR20050083827A (ko) | 서방성 l-아르기닌 포뮬레이션 및 이의 제조방법 및 용도 | |
US20070197602A1 (en) | Combined pharmaceutical composition | |
CN101795684A (zh) | 他汀类化合物与抗肥胖药的组合 | |
WO2008010008A2 (en) | Cardiovascular combinations using rennin-angiotensin inhibitors | |
CN100566716C (zh) | 治疗高血脂症的组合物 | |
CN103239725A (zh) | 一种治疗心脑血管疾病复方制剂 | |
CN1925857A (zh) | 治疗高血脂症的组合物 | |
WO2005123082A1 (fr) | Composition anti-hyperlipemie | |
CN104127391A (zh) | 一种含有阿托伐他汀钙的固体药物组合物 | |
US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
CN100358526C (zh) | 治疗高血脂症的组合物 | |
CN100566717C (zh) | 治疗高血脂症的组合物 | |
CN101357132B (zh) | 治疗高血脂症的组合物 | |
WO2020028124A1 (en) | NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS | |
CN113134086B (zh) | 一种降血脂的药物组合物 | |
CN1925858A (zh) | 治疗高血脂症的组合物 | |
WO2008015763A1 (fr) | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire | |
US20080146534A1 (en) | Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases | |
CN1929843A (zh) | 治疗高血脂症的组合物 | |
CN1332657C (zh) | 一种含洛伐他汀的组合物及其用途 | |
CN103393682A (zh) | 一种非洛地平复方药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000510 Denomination of invention: Composition for treating hyperlipoidemia Granted publication date: 20091209 License type: Exclusive License Open date: 20090204 Record date: 20100908 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000510 Date of cancellation: 20121226 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090204 Assignee: LUNNAN BETTER PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2013370000265 Denomination of invention: Composition for treating hyperlipoidemia Granted publication date: 20091209 License type: Exclusive License Record date: 20131210 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091209 |